In the EG.7-OVA tumor mouse model, the study demonstrated significant delay in tumor growth, extended survival, and concurrently induced the infiltration and activation of antigen-specific CD8+ T cells within the TME, thereby improving targeted delivery efficiency (219). Here, CD8A is linked to neoplasm.